1. Home
  2. NHI vs ERAS Comparison

NHI vs ERAS Comparison

Compare NHI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Health Investors Inc.

NHI

National Health Investors Inc.

HOLD

Current Price

$80.52

Market Cap

3.8B

Sector

Real Estate

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$19.29

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NHI
ERAS
Founded
1991
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.0B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
NHI
ERAS
Price
$80.52
$19.29
Analyst Decision
Buy
Strong Buy
Analyst Count
5
12
Target Price
$87.00
$14.25
AVG Volume (30 Days)
834.2K
5.6M
Earning Date
05-04-2026
05-08-2026
Dividend Yield
4.81%
N/A
EPS Growth
N/A
36.23
EPS
0.82
N/A
Revenue
$375,628,000.00
N/A
Revenue This Year
$15.44
N/A
Revenue Next Year
$10.01
N/A
P/E Ratio
$97.50
N/A
Revenue Growth
12.07
N/A
52 Week Low
$67.94
$1.33
52 Week High
$91.38
$24.28

Technical Indicators

Market Signals
Indicator
NHI
ERAS
Relative Strength Index (RSI) 63.89 59.23
Support Level $77.86 $17.63
Resistance Level $81.01 $21.60
Average True Range (ATR) 1.62 1.29
MACD 0.33 -0.16
Stochastic Oscillator 85.76 41.03

Price Performance

Historical Comparison
NHI
ERAS

About NHI National Health Investors Inc.

National Health Investors Inc is a self-managed REIT that owns, leases, operates, and finances the development of senior housing communities and medical facilities. It operates through two segments: Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates the majority of revenue, includes real estate leases, mortgages, and other notes receivable related to independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment consists of ventures that own and operate independent living facilities. The company's revenues are derived from rental income, interest and other income, and resident fees and services.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: